LabVantage Acquires SEIN Infotech South Korea to Expand Environmental Compliance Offerings and Further Growth in APAC Region
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, today announced the acquisition of software innovator SEIN Infotech South Korea, known for its robust environmental, health, and safety (EHS) management applications. This move strategically expands LabVantage's capabilities in the Asia-Pacific (APAC) region, particularly enhancing its environmental compliance offerings and enabling the company to provide an unrivaled, industry-first integrated informatics platform with EHS management solutions for the global energy and chemical industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530178403/en/
Michel Gerlicher, President of LabVantage International (R), and Jung Moon Lee, CEO of SEIN Infotech (L), seal the acquisition with a handshake. (Photo: Business Wire)
Responding to the increasing demands for advanced EHS solutions across the global market, LabVantage’s acquisition of South Korea-based SEIN Infotech aims to fortify its laboratory informatics suite to meet the stringent compliance and safety standards required in critical industries. As a trusted partner of LabVantage since 1999, SEIN Infotech has established itself as a leading system integrator in the energy and chemical sectors, providing clients with exceptional Quality and EHS Management Solutions.
Michel Gerlicher, President of LabVantage International, stated, “It is with great pleasure that we welcome SEIN Infotech's talented team and their loyal clients into the LabVantage family. The SEIN team’s experience and insights will enrich our organization as we join forces with them. We are more than just a LIMS company – at LabVantage, we aim to empower labs to transform scientific data into valuable business insights. With SEIN now officially recognized as a LabVantage group company, we're ready to deliver even greater value to our clients and expand our environmental compliance offerings.”
Jung Moon Lee, CEO of SEIN Infotech South Korea, commented, “We are excited to become a part of the LabVantage group and integrate our distinctive EHS solutions into the group’s robust informatics platform. This collaboration will extend our reach and impact, driving greater innovation and service excellence across the industry. Together, we will accelerate growth and set new standards in environmental compliance for our global clientele.”
LabVantage’s laboratory informatics platform goes beyond traditional LIMS, offering advanced features such as AI-powered solutions that enhance data integrity, strengthen cybersecurity, and accelerate digital transformation. The SEIN Infotech acquisition underscores LabVantage's commitment to innovation and excellence in laboratory informatics, ensuring clients receive optimal support for achieving regulatory compliance and operational safety.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
About SEIN Infotech South Korea
SEIN Infotech Co., Ltd. is a specialized company dedicated to advancing corporate management and informatization and is the first in Korea to provide an integrated information system for environment, health, and safety (EHS). We are leading the way in developing comprehensive solutions for EHS, quality, and waste management that are widely adopted by many domestic companies, ensuring seamless integration into enterprise IT frameworks. Committed to technological innovation, we strive to drive efficiency and excellence in enterprise IT. For more information, visit sein-it.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530178403/en/
Contact information
Media:
Charya Wickremasinghe, Ph.D.
Brandwidth Solutions LLC
cwickremasinghe@brandwidthsolutions.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 17:00:00 CEST | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm
Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 00:40:00 CEST | Press release
Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing
Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 20:46:00 CEST | Press release
Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s
Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 16:20:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 12:00:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom